The British High Commission has announced the India premiere of 'Lifeline', a Scottish musical that leverages storytelling and live performance to highlight the public health risks of antimicrobial resistance (AMR). The 60-minute production, featuring West End and Broadway artists, was staged at the British Council in New Delhi, bringing together senior figures from the Indian government, philanthropy, industry, academia, and the healthcare sector.
Understanding Antimicrobial Resistance
Antimicrobial resistance occurs when medicines become ineffective against infections, posing a serious and growing threat to public health worldwide. The musical aims to communicate this complex issue in an accessible and emotionally engaging way.
Sarah Cooper, Minister Counsellor and Director for Climate, Development, Science and Technology at the British High Commission, stated: "Drug-resistant infections pose a serious and growing threat to people in both our countries and across the world. The UK and India have been working shoulder to shoulder on this challenge for years, investing in research, strengthening laboratories, developing new diagnostics, and building the evidence base we need to act."
Future Plans for the Musical
A multi-city tour of the full production is planned in India for 2027. Cooper emphasized that tackling AMR is not solely the responsibility of scientists and policymakers but a conversation that belongs to everyone. She noted: "By bringing the world-class performance to New Delhi, we are taking that message to new audiences in a way that is bold, creative, and genuinely moving."
UK-India Collaboration on AMR
Technology and innovation, including healthcare, are priorities under the UK-India Vision 2035. AMR is central to the shared commitment to pandemic preparedness and joint work on vaccines. The collaboration spans research, innovation, diagnostics, laboratory strengthening, and surveillance across human health, animals, and the environment.
UK Research and Innovation has invested over £10 million through multiple research programmes. The Fleming Fund has contributed approximately £600,000 for laboratory strengthening and surveillance in India. Additionally, a £4.8 million partnership between the UK's Global Innovation Fund for drug resistance and Bengaluru's Centre for Cellular and Molecular Platforms focuses on environmental threats, supporting innovations such as tools to remove antibiotic residues from wastewater and portable devices for monitoring resistance in the field.
